AtriCure (ATRC) vs iRhythm (IRTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AtriCure (ATRC) has outperformed iRhythm (IRTC) over the past year, gaining 50.6% versus a loss of 40.9%. Over five years, IRTC leads with a +45.2% price change compared with -26.0% for ATRC. iRhythm is the larger company by market cap ($3.38 billion vs $2.69 billion), about 1.3 times the size.
On valuation, iRhythm trades at a lower forward P/E (80.1x vs 121.8x for AtriCure). AtriCure converts more of its revenue into profit, with a net margin of -2.1% versus -6.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRC | IRTC |
|---|---|---|
| Share price | $52.84 | $102.60 |
| Market cap | $2.69B | $3.38B |
| 1-day change | -0.88% | -2.28% |
| YTD return | +33.57% | -40.83% |
| 1-year return | +50.63% | -40.89% |
| 5-year return | -25.96% | +45.23% |
| P/E ratio (TTM) | 251.62 | — |
| Forward P/E | 121.76 | 80.06 |
| EPS (TTM) | $0.21 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $534.53M | $747.14M |
| Revenue growth (YoY) | +14.88% | +26.24% |
| Net income (latest FY) | $-11.45M | $-44.55M |
| Gross margin | 74.98% | 70.57% |
| Operating margin | -1.77% | -7.68% |
| Net margin | -2.14% | -5.96% |
| 52-week high | $61.70 | $212.00 |
| 52-week low | $25.36 | $100.70 |
| Distance from 52-week high | -14.36% | -51.60% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +3.88% | +69.52% |
| Average volume | 1.08M | 567.98K |
| Shares outstanding | 50.87M | 32.96M |
| Employees | 1,350 | 2,400 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATRC has outperformed IRTC by 91.5 percentage points over the past year.
- iRhythm grew revenue faster in its latest fiscal year (+26.24% vs +14.88%).
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Health Care · Medical/Dental Instruments · 1,350 employees
About iRhythm
IRTC stock →iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Health Care · Medical/Dental Instruments · 2,400 employees
ATRC vs IRTC FAQ
Which is bigger, AtriCure or iRhythm?
iRhythm (IRTC) is larger, with a market capitalization of $3.38B compared with $2.69B for AtriCure (ATRC).
Which stock has performed better over the past year, ATRC or IRTC?
ATRC returned +50.63% over the past 12 months, compared with -40.89% for IRTC (price return, excluding dividends). Past performance does not predict future results.
Are AtriCure and iRhythm in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.